Sponsored Content by Newcells BiotechReviewed by Olivia FrostNov 22 2024
A client wanted to know how three compounds affected the fibroblast-to-myofibroblast (FMT) transition and whether they had anti-fibrotic effects. The client sought a supplier for high-content imaging (HCI) for the analysis.
Image Credit: Newcells Biotech
Solution
Step 1:
Newcells' experts worked with the client to understand the problem
The client wanted to gain thorough insights into the compounds' anti-fibrotic effects, including quantitative dose responses and how each compound affected alpha-smooth muscle actin and extracellular collagen I deposited using an FMT assay.
Step 2:
Newcells created a study protocol and design that efficiently provided data of value
The experiment assessed three chemicals' effects on simulated primary lung fibroblasts. The compounds were administered to the fibroblasts before activation by external stimuli to recreate fibrotic illness.
The results were analyzed using HCI, which quantified the expression of extracellular collagen I and alpha-smooth muscle actin.
Step 3:
From initiation to data in just over one month
The study consists of the experimental phase, data processing and analysis, and the presentation of a data summary to the client.
DATASET: Three test articles, three positive controls, 10 conditions per test article, and six technical replicates per condition. Each data point will be collected in triplicate and replicated with primary fibroblasts obtained from three healthy volunteers.
The experiment was carried out in 384-well plates. Immunofluorescence assessed alpha-smooth muscle actin and collagen I deposition for each data point.
The investigation, which included over 1000 data points, was finished just over a month after the contract agreement.
Step 4:
Newcells delivers a detailed report with a reliable dataset
Newcells provided the client with a robust dataset that included raw and normalized data, statistical analysis, and representative immunofluorescence images.
Outcomes for the client
Newcells worked with its client to understand the data and prepared a thorough report with all requested information.
About Newcells Biotech
Newcells Biotech develops in vitro cell-based assays for drug and chemical discovery and development.
Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology, and organoid technology, we build models that incorporate the "best biology" for predicting in vivo behavior of new drugs.
Our experts have developed and launched assays to measure transporter function, safety, and efficacy in a range of cell and tissue types, including kidney, retina and lungs.
We have the capability to develop and implement protocols to measure cilia beat frequency and toxicity on small airway epithelial cells model, retinal toxicity and disease modelling on retinal organoids and retina epithelium, as well as drug transport in the kidney, DDI and nephrotoxicity across human and a range of preclinical species.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.